Back to Directory
Aethox Therapeutics
Greater London
Founded 2025
Small-molecule HO-1 inhibitors to overcome chemotherapy resistance in tumours
Aethox Therapeutics is a preclinical biotechnology company developing small-molecule drugs that help solid tumours respond to chemotherapy and other standard cancer treatments.
Its lead approach targets heme oxygenase-1 (HO-1), an enzyme produced by tumour-associated macrophages that can block cancer-fighting T cells from entering tumours.
Inhibiting HO-1 alongside chemotherapy is intended to strengthen the anti-tumour immune response.
The company is preparing its first-in-class oral candidate for early clinical trials.